M. D. Della Porta

发表

A practical algorithm for acute myeloid leukaemia diagnosis following the updated 2022 classifications.

M. Voso, A. Rambaldi, M. D. Della Porta, 2024, Critical reviews in oncology/hematology.

Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium

Xingmin Feng, N. Daver, L. Adès, 2024, HemaSphere.

Myelodysplastic/Myeloproliferative Neoplasms with Features Intermediate between Primary Myelofibrosis and Chronic Myelomonocytic Leukemia: Case Series and Review of the Entity

A. Bonometti, S. Fraticelli, Simone Zanella, 2024, Hemato.

Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosis

M. Tormo, M. Díaz-Beyá, L. Zamora, 2024, Frontiers in oncology.

MOSAIC: An Artificial Intelligence–Based Framework for Multimodal Analysis, Classification, and Personalized Prognostic Assessment in Rare Cancers

Pierandrea Morandini, V. Savevski, I. Prada-Luengo, 2024, JCO clinical cancer informatics.

Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and Microsimulation

M. Díez-Campelo, R. Komrokji, C. Tentori, 2024, JCO clinical cancer informatics.

Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms

V. Santini, B. Peruzzi, U. Oelschlaegel, 2024, Leukemia.

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)

R. Bejar, U. Borate, J. Giesinger, 2024, HemaSphere.

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

M. Cazzola, G. Mufti, P. Fenaux, 2013, Blood.